

Minutes of the **Prescribing and Medicines Management Group** held in **Meeting Room 2, Wynford House, Lufton Way, Yeovil, Somerset, on Wednesday, 18<sup>th</sup> April 2018.**

Present:

Dr Helen Cotton (HC)	South Somerset Representative
Dr David Davies (DD)	West Somerset Representative
Dr Adrian Fulford (AF)	Taunton Representative
Shaun Green (SG)	Associate Director, Head of Medicines Management
Liz Harewood (LH)	Somerset Partnership Deputy Chief Pharmacist
Catherine Henley (CH)	Locality Medicines Manager
Gordon Jackson (GJ)	Lay Representative
Dr Piers Jennings (PJ)	East Mendip Representative
Dr Catherine Lewis (CL)	Bridgwater Representative
Dr Barry Moyses (BM)	LMC Representative
Dr Geoff Sharp (GS)	Chairman, CCG Prescribing Lead
Zoe Talbot-White (ZTW)	Secretary
Caroline Taylor (CT)	Secretary
Emma Waller (EW)	Pharmacist, LPC Representative, Somerset

Apologies:	Steve Du Bois (SDB)	Somerset Partnership Chief Pharmacist
	Dr Toby Burne (TB)	CLICK Representative
	Sam Morris (SM)	Locality Medicines Manager
	Dr James Nicholls (JN)	GP, West Mendip Representative

**1 Introductions:**  
GS welcomed Dr Barry Moyses (BM) as the new LMC rep and Emma Waller (EW) as the LPC rep who was particularly welcomed by the Committee. Welcome also made to Caroline Taylor the committee's new Secretary'.

**2 Apologies for absence:**  
Apologies were provided as detailed above.

**3 Declarations of interest**

None this month

BM to provide his declarations of interest

**Action: ZTW**

CH to send link to enable PAMM members to complete 'Conflicts of Interest in the NHS' training online.

**Action : CH**

**4 Minutes of the meeting on 14<sup>th</sup> March 2018**

**4.1** Agreed as an accurate record of the meeting.

## 4.2 Review of Action points

Most items were either complete or on the agenda. The following points were specifically noted:

- **Action 1: Prescribing requests for OTC medications for children's use in care settings** SG to resend Wessex letter to BM, who will organise for LMC to amend for use in Somerset and send out.  
**Action:SG & BM**
- **Action 2: Catheter Trays** -SG re-iterated that the CCG do not recommend recommend that GPs prescribe catheter trays because there is no evidence that they reduce infection rates for patients.
- **Action 3: Audit on antipsychotic prescribing in people with learning disabilities;** Agreed that SomPar will bring back recommendations arising from secondary analysis for discussion.  
**Action: LH**
- **Action 4: Draft single SCG for Disease Modifying Drugs;** Edit document to include GP option to decline taking over prescribing responsibility within two weeks of request. Bring back to PAMM in May.  
**Action: CH**  
The 'NB' medical education one page document on DMARD monitoring needs to be amended before use in primary care. CH to highlight to authors.  
**Action: CH**
- **Action 5: Dementia diagnosis guideline;** New meeting to be scheduled, SG to provide feedback after meeting.  
**Action:SG**
- **Action 6: NHS Community Pharmacy Contractual Framework Essential Service – Repeat Dispensing** EPS4 expected by October 2018. SG suggested that practices start providing 'batch prescriptions for long-term, stable pts. SG will bring any new information back to PAMM.  
**Action:SG**
- **Action 7: Vitamins post Bariatric Surgery;** SG highlighted that there is a contracting issue around the post-operative monitoring and follow up of these patients. Trusts should be supplying any necessary liquid specials for inpatients. It was noted that GPs would welcome individual patient action plans.
- **Action 10: Drugs prolonging QT interval;** GS to contact Justin Harrington (CCG IT lead) regarding raising at Emis user group.  
**Action: GS**
- **Action 12: EMIS viewer trial- Ilminster;** Noted that the trial will go live 5<sup>th</sup> June, with a formal review 19<sup>th</sup> September. Andy Hill will keep MM team informed.
- **Action 16: Palliative care MAR;** MAR chart under development by SomPar has now been tested and SomPar hope for it to be available soon. The MAR chart is pre-populated and can be printed via EMIS. Advise PAMM when available. **Action: LH**
- **Action 17: St Margaret's cellulitis and lymphedema** treatment; CH has passed query on to Ana Alves and will update PAMM on the outcome when available.  
**Action: CH**

**PART 1 – ITEMS FOR DISCUSSION OR DECISION**

5

**Matters Arising**

5.1

**An audit on Antipsychotic prescribing in people with learning disabilities**

Discussed during Action point review – Action 3

5.2

**NHS England: Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs**

NHS England have recommended that GPs do not routinely prescribe for conditions, for which treatment can be easily purchased OTC. However, none of these products are blacklisted on FP10. SG pointed out that the GMS contract requires GPs, where there is a clinical need, to provide either prescription or, healthcare advice.

CCG guidance around ‘self-care’ is already in place and Scorecard indicator for 2018/19 has been introduced. It was noted that Somerset is already in the lowest 5% in the country for prescribing these products. Newsletter article to go out explaining that there is no expectation that GPs will prescribe in these conditions but GPs retain their clinical freedom to do so.

**Action: Steve Moore**

MMT to check that the all products and conditions covered by the NHSE items are mentioned in CCG MMT self-care promotional materials and provide community pharmacies information

**Action: Joanne Ayre**

5.3

**Somerset CCG Repeat dispensing letter to pharmacy contractors**

Discussed during Action point review – Action 6

5.4

**Somerset Pathology records access**

The IT department is liaising with NHSE to give GPs access to patient’s records – keep under review

5.5

**Budget update and amendment to scorecard**

As there are very small savings in switching venlafaxine products now, PAMM agreed to remove venlafaxine indicator from the scorecard for 18/19 and add Eclipse live data extraction indicator, instead. MMT to check that the number of practice’s on Eclipse Live analysis report is correct.

**Action: SM**

NCSO issue will remain for this financial year creating a burden on the CCG prescribing budget for the next year.

Prescribing budget being reduced by £3M to take account of rosuvastatin patent expiry

6

**Other Issues**

6.1

**QRISK3 web calculator**

Noted. NICE updates will be recommending QRISK3 as the recommended cardiac risk calculator. EMIS will be updated in due course.

6.2

**Medicines optimisation in care homes**

CCG has been allocated some money to commission pharmacists to undertake care home reviews. The MMT has submitted a proposal to release funding, the deadline for proposals was Friday 13<sup>th</sup> April 2018.

At the moment, around 60% of care home patients are being reviewed annually by the MMT.

Inform of bids at next PAMM meeting

**Action: SG**

- 6.3 NHS Counter Fraud Authority: Management and control of prescription forms: A guide for prescribers and health organisations**  
Guidance noted. Individual practices should ensure that they have their own robust arrangements in place.  
  
Highlight this document in the newsletter **Action: Steve Moore**
- 6.4 Summary of 2018/19 General Medical Services agreement**  
Noted
- 6.5 CQC & NHS England: High level guidance to support a shared view of quality in general practice**  
Nationally agreed and useful document. Noted.
- 7 Formulary Applications**
- 7.1 Testogel (Testosterone) 16.2mg/g gel in a Pump Formulation, Besins Healthcare.**  
**1x30g pump £31.11**  
Approved; **GREEN** TLS status; add to newsletter noting information on bioequivalence compared with sachets and update formulary.  
**Action: Steve Moore**
- 8 Reports from other meetings**
- 8.1 Feedback**
- 8.1 Commissioning Locality Feedback**  
**South Somerset** – HC – Asked whether the MMT could carry out the practice audits earlier in the year, so that a re-audit could be undertaken. SG explained that the MMT would only be able to do this if the practice is performing well against the scorecard indicators.  
  
**West Somerset** – DD – Nothing to note  
**Central Mendip** – GS – Nothing to note  
**Bridgwater Bay** – CL – Nothing to note  
**Taunton** – AF – Nothing to note  
**Chard, Crewkerne, Ilminster and Langport** – TB – Not present  
**East Mendip** – PJ – Nothing to note  
**West Mendip** – JN – Not present  
**North Sedgemoor** – No representative
- 8.2 COG Feedback**  
Potentially last COG meeting - information to follow  
**Summary**
- 8.3 Somerset Partnership Mental Health D&TC – Next Meeting 12/06/18**
- 8.4 YDH D&TC – Has been replaced by Medicines Committee meetings – Last meeting 28/03/18 – Minutes not received**  
CH attended the meeting and noted that edoxaban will be YDH first choice NOAC, going forwards but only if it is an appropriate choice for the individual patient.
- 8.5 TST D&TC – Last meeting 9/02/18- Previously discussed**

- 8.6 **BNSSG Joint Formulary Group – Last meeting 10/04/18 – Minutes not received**
- 8.7 **BNSSG D&TC — Last meeting 28/03/18 – Minutes not received**
- 8.8 **RUH Bath D&TC – Last meetings 08/03/18 & 12/04/18 – Minutes not received**
- 8.9 **Weston D&TC – Last meeting 08/03/18 – Minutes not received**
- 8.10 **T&S Antimicrobial Prescribing Group – Last meeting 14/02/18 postponed to 07/03/18 – Minutes not received**
- 8.11 **Somerset Antimicrobial Stewardship Group – Next meeting not scheduled**
- 8.12 **LPC Report**

LPC is working on:

- a Patient Safety Bulletin and Alert cards for community pharmacies to include CDs, Oramorph and 3 day rule for instalment dispensing.
- a project linking with the local Trusts to provide pre-conception care for Type II diabetics.

EW to send a copy of the Patient Safety bulletin to SG. **Action: EW**

- 8.13 **Somerset Medication Safety Network – Next meeting not scheduled**
- Part 2 – Items for Information or Noting**

**9 Current Performance**

**9.1 Prescribing Update**

Noted

- Forecast position is very encouraging position; improved by just under £1million; £649,000 over spend
- PBR excluded data remains variable. Biosimilar being launched in June / July this will have a positive impact on the budget.

**9.2 January Scorecard commissioning locality trend**

Noted; Improvement with 20 indicators good engagement

**9.3 January Safety spreadsheet**

Noted;

ZTW Highlighted two extra tabs

- List of Eclipse RADAR alerts actioned by practices that have allowed data to be shared
- List of major safety alerts confirmed actioned by practices (less than 50%). Practice managers and prescribing leads contacted to confirm safety alert actioned.

**9.4 Flu vaccine ski slopes**

Noted; This indicator is being remove from this year's scorecard

**10 Rebate Schemes**

**10.1** None authorised this month

**11 NICE Guidance April 18**

**12 NICE Technology Appraisals**

**12.1** None yet this month

- 13 NICE Clinical Guidance**
- 13.1 [NG87] Attention deficit hyperactivity disorder: diagnosis and management -New**
- This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
- Noted  
To check that Shared Care Guideline is in line with NG87; **Action: CH**
- 13.2 [NG88] Heavy menstrual bleeding: assessment and management -New**
- Noted  
Esmya Safety Alert has been shared
- 13.3 [NG90] Physical activity and the environment -New**
- Noted
- 13.4 [NG91] Otitis media (acute): antimicrobial prescribing -New**
- Noted; Ana Alves has confirmed CCG antimicrobial guidance is consistent with NG91
- 13.5 [NG92] Stop smoking interventions and services -New**
- Noted
- 13.6 [NG93] Learning disabilities and behaviour that challenges: service design and delivery -New**
- Noted
- 13.7 [NG94] Emergency and acute medical care in over 16s: service delivery and organisation -New**
- Noted
- 13.8 [NG95] Lyme disease -New**
- This guideline covers diagnosing and managing Lyme disease. It aims to raise awareness of when Lyme disease should be suspected and ensure that people have prompt and consistent diagnosis and treatment. It does not cover preventing Lyme disease.
- Ana Alves to confirm CCG antimicrobial guidance is consistent with NG95  
**Action: AA**
- 13.9 [NG96] Care and support of people growing older with learning disabilities -New**
- Noted
- 14 Safety Items, NPSA Alerts and Signals**
- 14.1 MHRA Drug Safety Update April**
- Not published yet this month
- 14.2 EMA New measures to avoid valproate exposure in pregnancy endorsed**
- Noted  
Awaiting MHRA recommendations before updating current pathway
- 15 BNF Changes**
- 15.1 BNF Update March**
- Noted  
Nothing new
- 16 Any other business**
- 16.1** HC raised concern around cefotaxime PCG. SG informed that due to change From OOH services to Devon Drs new PGDs would be brought to PAMM for approval.



**PRESCRIBING AND MEDICINES MANAGEMENT GROUP MEETINGS  
SCHEDULE OF ACTIONS**

NO	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	STATUS
<b>ACTIONS ARISING FROM THE MEETING HELD ON WEDNESDAY 18<sup>th</sup> April 2018</b>				
1	<b>Declarations of interest</b>	<ul style="list-style-type: none"> <li>Send link to enable PAMM members to complete 'Conflicts of Interest in the NHS' – training</li> <li>Obtain DOI's from Dr Moyse</li> </ul>	<b>Catherine Henley</b> <b>23<sup>rd</sup> May 2018</b>  <b>Zoe Talbot-White</b> <b>23<sup>rd</sup> May 2018</b>	Complete
2	<b>Prescribing requests for OTC medications for children's use in care settings</b>	<ul style="list-style-type: none"> <li>SG to resend Wessex letter to BM</li> <li>BM will complete letter and send out</li> </ul>	<b>Shaun Green</b> <b>Barry Moyse</b> <b>23<sup>rd</sup> May 2018</b>	Complete
3	<b>Antipsychotic prescribing in people with learning disabilities audit</b>	Recommendations and actions arising from secondary analysis to be brought back to PAMM.	<b>Liz Harewood</b> <b>23<sup>rd</sup> May 2018</b>	On agenda
4	<b>Draft single SCG for DMDs</b>	<ul style="list-style-type: none"> <li>To edit document and include GP option to decline taking over prescribing responsibility within two weeks of request. Bring back to PAMM in May.</li> <li>The 'NB' medical education one page document on DMARD monitoring needs to be amended before use in primary care. CH to highlight to authors.</li> </ul>	<b>Catherine Henley</b> <b>23<sup>rd</sup> May 2018</b>	On agenda
5	<b>Dementia diagnosis guideline</b>	New meeting to be scheduled, feedback after meeting.	<b>Shaun Green</b> <b>23<sup>rd</sup> May 2018</b>	
6	<b>Community Pharmacy Contract Framework Essential Service – Repeat Dispensing</b>	Bring any new information back to PAMM.	<b>Shaun Green</b> <b>23<sup>rd</sup> May 2018</b>	Letter sent to contractors
7	<b>EMIS Web Alerts</b>	To raise the number of alerts with Justin Harrington to see whether anything can be done via EMIS	<b>Geoff Sharp</b> <b>23<sup>rd</sup> May 2018</b>	
8	<b>SomPar Palliative care MAR chart</b>	Advise PAMM when available.	<b>Liz Harewood</b> <b>23<sup>rd</sup> May 2018</b>	
9	<b>St Margaret's cellulitis and lymphedema</b>	Update PAMM on outcome.	<b>Catherine Henley</b> <b>23<sup>rd</sup> May 2018</b>	
10	<b>NHS England: Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs</b>	<ul style="list-style-type: none"> <li>SM Add to newsletter no expectation to prescribe, GPs have clinical freedom</li> <li>JA To check that the 35 NHSE items are contained in CCG MMT self-care agenda. Once this is checked provide community pharmacies with the list of the 35 items</li> </ul>	<b>Steve Moore</b> <b>Joanne Ayre</b> <b>23<sup>rd</sup> May 2018</b>	Complete

NO	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	STATUS
11	Medicines optimisation in care homes	Inform PAMM of any bids at next meeting	<b>Shaun Green</b> 23 <sup>rd</sup> May 2018	On agenda
12	NHS Counter Fraud Authority: Management and control of prescription forms: A guide for prescribers and health organisations	Highlight this document in the newsletter	<b>Steve Moore</b> 23 <sup>rd</sup> May 2018	
13	Formulary Applications Testogel (Testosterone) 16.2mg/g gel in a Pump Formulation, Besins Healthcare. 1x30g pump £31.11	Approved <b>GREEN</b> TLS add to newsletter including info on bioavailability of pump vs sachets and update formulary	<b>Steve Moore</b> 23 <sup>rd</sup> May 2018	
14	NICE Clinical Guidance [NG87] Attention deficit hyperactivity disorder: diagnosis and management –New	CH to check that SCG is in line with NG87	<b>Catherine Henley</b> 23 <sup>rd</sup> May 2018	
15	[NG95] Lyme disease -New	AA to confirm CCG antimicrobial guidance is consistent with NG95	<b>Ana Alves</b> 23 <sup>rd</sup> May 2018	